Catalyst Pharma’s Chairman Cashes Out in Multi-Million Dollar Stock Sale!

New insider activity at Catalyst Pharma ( (CPRX) ) has taken place on June 10, 2025.

Patrick Mcenany, the Chairman of the Board of Directors at Catalyst Pharma, has recently sold 200,000 shares of the company’s stock. This transaction is valued at an impressive $5,217,197.

Recent Updates on CPRX stock

Catalyst Pharmaceuticals has recently seen significant developments, including the appointment of Dr. William Andrews as the new Chief Medical Officer, succeeding Dr. Gary Ingenito who is retiring but will remain as a consultant during the transition. This leadership change is expected to bolster Catalyst’s strategic initiatives in rare diseases, given Dr. Andrews’s extensive experience in the biopharmaceutical industry. Additionally, the company held its 2025 Annual Stockholders Meeting where several directors were elected, and amendments to the Stock Incentive Plan were approved. Analysts have maintained a ‘Buy’ rating for Catalyst Pharma, driven by the company’s strong financial performance, robust revenue growth, and promising revenue guidance. However, potential challenges such as cash flow volatility and generic competition for FYCOMPA remain considerations for investors.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s strong financial performance and positive earnings outlook are key drivers of its high score. Bullish technical indicators and reasonable valuation further support the stock’s potential, despite some cash flow volatility and upcoming challenges in product revenue.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

YTD Price Performance: 20.07%

Average Trading Volume: 1,270,972

Technical Sentiment Signal: Buy

Current Market Cap: $3.16B